CureVac N.V. CVAC Financial Statement Data


2025 Q2

Submissions

Field Row 1 Row 2
adsh 0001410578-25-001369 0001410578-25-000692
cik 1809122 1809122
name CUREVAC N.V. CUREVAC N.V.
sic 2834 2834
countryba DE DE
stprba
cityba BADEN-WURTTEMBERG BADEN-WURTTEMBERG
zipba 72076 72076
bas1 PAUL-EHRLICH-STRABE 15 TUBINGEN PAUL-EHRLICH-STRABE 15 TUBINGEN
bas2
baph 49 7071 9883 0 49 7071 9883 0
countryma DE DE
stprma
cityma BADEN-WURTTEMBERG BADEN-WURTTEMBERG
zipma 72076 72076
mas1 PAUL-EHRLICH-STRABE 15 TUBINGEN PAUL-EHRLICH-STRABE 15 TUBINGEN
mas2
countryinc NL NL
stprinc
ein 000000000 000000000
former CUREVAC B.V. CUREVAC B.V.
changed 20200410 20200410
afs 2-ACC 2-ACC
wksi 0 0
fye 1231 1231
form 6-K 20-F
period 20250331 20241231
fy 2025 2024
fp Q1 FY
filed 20250520 20250411
accepted 2025-05-20 16:23:00.0 2025-04-10 17:59:00.0
prevrpt 0 0
detail 1 1
instance cvac-20250331x6k_htm.xml cvac-20241231x20f_htm.xml
nciks 1 1
aciks

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
cik Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings.
name Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date.
sic Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business.
countryba The ISO 3166-1 country of the registrant's business address.
stprba The state or province of the registrant’s business address, if field countryba is US or CA.
cityba The city of the registrant's business address.
zipba The zip code of the registrant’s business address.
bas1 The first line of the street of the registrant’s business address.
bas2 The second line of the street of the registrant’s business address.
baph The phone number of the registrant’s business address.
countryma The ISO 3166-1 country of the registrant's mailing address.
stprma The state or province of the registrant’s mailing address, if field countryma is US or CA.
cityma The city of the registrant's mailing address.
zipma The zip code of the registrant’s mailing address.
mas1 The first line of the street of the registrant’s mailing address.
mas2 The second line of the street of the registrant’s mailing address.
countryinc The ISO 3166-1 country of incorporation for the registrant.
stprinc The state or province of incorporation for the registrant, if countryinc is US or CA.
ein Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States.
former Most recent former name of the registrant, if any.
changed Date of change from the former name, if any.
afs Filer status with the SEC at the time of submission:
1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned.
wksi Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement.
fye Fiscal Year End Date, rounded to nearest month-end.
form The submission type of the registrant’s filing.
period Balance Sheet Date, rounded to nearest month-end.
fy Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8).
fp Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year.
filed The date of the registrant’s filing with the Commission.
accepted The acceptance date and time of the registrant’s filing with the Commission.
prevrpt Previous Report – TRUE indicates that the submission information was subsequently amended.
detail TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount).
instance The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol.
nciks Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing.
aciks Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information.

Numbers

adsh ddate tag value uom qtrs version segments coreg footnote
0001410578-25-000692 20221231 Cash Flows From Used In Investing Activities -93499000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Depreciation And Amortisation Expense 18763000.0000 EUR 4 ifrs/2024 Attribution Of Expenses By Nature To Their Function= Operative Expenses;
0001410578-25-000692 20211231 Equity -5817000.0000 EUR 0 ifrs/2024 Components Of Equity= Treasury Shares;
0001410578-25-000692 20231231 Equity And Liabilities 788249000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 General And Administrative Expense 69690000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Income Tax Expense Continuing Operations 28695000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Intangible Assets And Goodwill 28347000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Interest Paid Classified As Operating Activities 2325000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners 10467000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Other Comprehensive Income 105000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Other Noncurrent Assets 1702000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Payments Of Lease Liabilities Classified As Financing Activities 5114000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Proceed From Issuing Other Equity Instrument Or Exercise Of Options 910000.0000 EUR 4 0001410578-25-000692
0001410578-25-000692 20231231 Proceed From Issuing Other Equity Instrument Or Exercise Of Options 246000.0000 EUR 4 0001410578-25-000692
0001410578-25-000692 20230228 Proceeds From Issuing Shares 219832000.0000 EUR 0 ifrs/2024 Ifrs Sale Of Stock= Closing Of Public Offering Of Common Shares;
0001410578-25-000692 20241231 Profit Loss 162186000.0000 EUR 4 ifrs/2024 Components Of Equity= Retained Earnings;
0001410578-25-000692 20221231 Profit Loss From Operating Activities -249457000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Property Plant And Equipment 26467000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Buildings;
0001410578-25-000692 20231231 Property Plant And Equipment 236782000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Property Plant And Equipment 8038000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Cumulative Amortization And Impairment; Classes Of Property Plant And Equipment= Other Property Plant And Equipment;
0001410578-25-000692 20231231 Purchase Of Intangible Assets Classified As Investing Activities 2880000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Revenue From Contracts With Customers 3370000.0000 EUR 4 ifrs/2024 Geographical Areas= C H; Major Customers= Crispr;
0001410578-25-000692 20231231 Revenue From Contracts With Customers 5425000.0000 EUR 4 ifrs/2024 Counterparty Name= Crispr Therapeutics;
0001410578-25-000692 20231231 Revenue From Contracts With Customers 1197000.0000 EUR 4 ifrs/2024 Geographical Areas= N L; Major Customers= Genmab;
0001410578-25-000692 20241231 Revenue From Contracts With Customers 19146000.0000 EUR 4 ifrs/2024 Counterparty Name= Glaxosmithkline; Ifrs Type Of Arrangement= Glaxosmithkline Covid Agreement;
0001410578-25-000692 20241231 Revenue From Contracts With Customers 12947000.0000 EUR 4 ifrs/2024 Geographical Areas= C H; Major Customers= Crispr;
0001410578-25-000692 20221231 Rightofuse Assets 41183000.0000 EUR 0 ifrs/2024 Classes Of Assets= Land And Buildings;
0001410578-25-000692 20241231 Sales And Marketing Expense 4447000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Settlement Of Share Based Payment Awards Amount 26000.0000 EUR 4 0001410578-25-000692 Components Of Equity= Issued Capital;
0001410578-25-000692 20241231 Settlement Of Share Based Payment Awards Amount -131000.0000 EUR 4 0001410578-25-000692
0001410578-25-000692 20241231 Accumulated Other Comprehensive Income 39000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20221231 Adjustments For Decrease Increase In Inventories -47851000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Adjustments For Increase Decrease In Provisions -58799000.0000 EUR 4 0001410578-25-000692
0001410578-25-000692 20241231 Adjustments For Sharebased Payments 4121000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Adjustments Transfer To Asset Held For Sale 19064000.0000 EUR 4 0001410578-25-000692
0001410578-25-000692 20241231 Assets 802827000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Basic Earnings Loss Per Share -1.1800 EUR 4 ifrs/2024
0001410578-25-000692 20211231 Cash And Cash Equivalents 811464000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Comprehensive Income 162186000.0000 EUR 4 ifrs/2024 Components Of Equity= Retained Earnings;
0001410578-25-000692 20231231 Current Assets 478381000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Current Contract Assets 2758000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Current Lease Liabilities 5321000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Current Liabilities 186389000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Deferred Tax Liabilities 409000.0000 EUR 0 ifrs/2024 Temporary Difference Unused Tax Losses And Unused Tax Credits= Ifrs Cash And Cash Equivalents;
0001410578-25-000692 20221231 Depreciation And Amortisation Expense 6295000.0000 EUR 4 ifrs/2024 Attribution Of Expenses By Nature To Their Function= Cost Of Sales;
0001410578-25-000692 20231231 Depreciation And Amortisation Expense 27229000.0000 EUR 4 ifrs/2024 Attribution Of Expenses By Nature To Their Function= Operative Expenses;
0001410578-25-000692 20211231 Equity -1056785000.0000 EUR 0 ifrs/2024 Components Of Equity= Retained Earnings;
0001410578-25-000692 20221231 Equity -1305814000.0000 EUR 0 ifrs/2024 Components Of Equity= Retained Earnings;
0001410578-25-000692 20241231 Equity 696608000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Finance Costs 829000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Ifrs Stock Issued During Period Value New Issues -66484000.0000 EUR 4 0001410578-25-000692
0001410578-25-000692 20241231 Income Tax Expense Continuing Operations 385132000.0000 EUR 4 ifrs/2024 Significant Investments In Subsidiaries= Curevac Manufacturing Gmbh;
0001410578-25-000692 20231231 Inventories 24801000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20221231 Issue Of Equity 829000.0000 EUR 4 ifrs/2024 Components Of Equity= Issued Capital;
0001410578-25-000692 20221231 Profit Loss -249029000.0000 EUR 4 ifrs/2024 Components Of Equity= Retained Earnings;
0001410578-25-000692 20241231 Profit Loss From Operating Activities 177682000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Property Plant And Equipment 37416000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Technical Equipment And Machines And Other Equipment;
0001410578-25-000692 20231231 Property Plant And Equipment 12914000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Cumulative Amortization And Impairment; Classes Of Property Plant And Equipment= Buildings;
0001410578-25-000692 20231231 Property Plant And Equipment 54941000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Technical Equipment And Machines And Other Equipment;
0001410578-25-000692 20231231 Property Plant And Equipment 176790000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Construction In Progress;
0001410578-25-000692 20231231 Property Plant And Equipment 4698000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Other Property Plant And Equipment;
0001410578-25-000692 20241231 Property Plant And Equipment 34436000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Cumulative Amortization And Impairment; Classes Of Property Plant And Equipment= Construction In Progress;
0001410578-25-000692 20241231 Property Plant And Equipment 283478000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount;
0001410578-25-000692 20241231 Property Plant And Equipment 59612000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Technical Equipment And Machines And Other Equipment;
0001410578-25-000692 20241231 Property Plant And Equipment 3209000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Other Property Plant And Equipment;
0001410578-25-000692 20221231 Purchase Of Intangible Assets Classified As Investing Activities 5199000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Retained Earnings -1565981000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Share Based Payment Expense Incl. Deferred Taxes 7697000.0000 EUR 4 0001410578-25-000692 Components Of Equity= Capital Reserve;
0001410578-25-000692 20221231 Revenue From Contracts With Customers 67420000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Revenue From Contracts With Customers 1787000.0000 EUR 4 ifrs/2024 Geographical Areas= N L; Major Customers= Genmab;
0001410578-25-000692 20221231 Revenue From Contracts With Customers 3062000.0000 EUR 4 ifrs/2024 Products And Services= Ifrs Product; Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred At Point In Time;
0001410578-25-000692 20231231 Revenue From Contracts With Customers 11312000.0000 EUR 4 ifrs/2024 Products And Services= Ifrs Product; Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred At Point In Time;
0001410578-25-000692 20241231 Revenue From Contracts With Customers 416173000.0000 EUR 4 ifrs/2024 Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred At Point In Time;
0001410578-25-000692 20231231 Rightofuse Assets 39574000.0000 EUR 0 ifrs/2024 Classes Of Assets= Land And Buildings;
0001410578-25-000692 20241231 Comprehensive Income 162291000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Deferred Tax Liabilities 12052000.0000 EUR 0 ifrs/2024 Temporary Difference Unused Tax Losses And Unused Tax Credits= Rightofuse Assets;
0001410578-25-000692 20241231 Deferred Tax Liabilities 883000.0000 EUR 0 ifrs/2024 Temporary Difference Unused Tax Losses And Unused Tax Credits= Intangible Assets;
0001410578-25-000692 20221231 Depreciation And Amortisation Expense 23741000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Depreciation And Amortisation Expense 13821000.0000 EUR 4 ifrs/2024 Attribution Of Expenses By Nature To Their Function= Ifrs General And Administrative Expense;
0001410578-25-000692 20221231 Property Plant And Equipment 197941000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Adjustments For Finance Costs 333000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Adjustments For Other Operating Expense Income -227000.0000 EUR 1 0001410578-25-001369
0001410578-25-001369 20240331 Adjustments For Provisions 17062000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Capital Reserve 2075624000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20231231 Cash And Cash Equivalents 402452000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Comprehensive Income -113000.0000 EUR 1 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001410578-25-001369 20250331 Comprehensive Income -52084000.0000 EUR 1 ifrs/2024 Components Of Equity= Retained Earnings;
0001410578-25-001369 20240331 Cost Of Sales 41690000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20241231 Current Liabilities 72348000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Current Liabilities 61290000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20241231 Deferred Tax Liabilities 227000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Depreciation And Amortisation Expense 1028000.0000 EUR 1 ifrs/2024 Attribution Of Expenses By Nature To Their Function= Cost Of Sales;
0001410578-25-001369 20231231 Equity 516941000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Equity -1636534000.0000 EUR 0 ifrs/2024 Components Of Equity= Retained Earnings;
0001410578-25-001369 20241231 Equity 2073444000.0000 EUR 0 ifrs/2024 Components Of Equity= Capital Reserve;
0001410578-25-001369 20241231 Equity And Liabilities 802827000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Interest Received Classified As Operating Activities 3294000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Inventories 541000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20241231 Liabilities 106219000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Noncurrent Lease Liabilities 32182000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Other Comprehensive Income -56000.0000 EUR 1 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001410578-25-001369 20250331 Other Current Liabilities 26392000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Other Noncurrent Assets 1514000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Purchase Of Intangible Assets Classified As Investing Activities 14000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Purchase Of Property Plant And Equipment Classified As Investing Activities 484000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Revenue From Contracts With Customers 6000.0000 EUR 1 ifrs/2024 Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred At Point In Time;
0001410578-25-001369 20250331 Settlement Of Share Based Payment Awards Amount 99000.0000 EUR 1 0001410578-25-001369 Components Of Equity= Issued Capital;
0001410578-25-001369 20250331 Tax Benefit Arising From Previously Unrecognised Tax Loss Tax Credit Or Temporary Difference Of Prior Period Used To Reduce Current Tax Expense 1122000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Accumulated Other Comprehensive Income -74000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Cash And Cash Equivalents 438331000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Cash Flows From Used In Financing Activities -1312000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Comprehensive Income -70609000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20241231 Current Provisions 1956000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20241231 Current Tax Liabilities 18254000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20241231 Current Trade Receivables 14077000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Current Trade Receivables 1870000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Deferred Tax Liabilities 227000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Depreciation And Amortisation Expense 2231000.0000 EUR 1 ifrs/2024 Attribution Of Expenses By Nature To Their Function= Ifrs General And Administrative Expense;
0001410578-25-001369 20231231 Equity 2056110000.0000 EUR 0 ifrs/2024 Components Of Equity= Capital Reserve;
0001410578-25-001369 20231231 Equity 26879000.0000 EUR 0 ifrs/2024 Components Of Equity= Issued Capital;
0001410578-25-001369 20241231 Equity 26921000.0000 EUR 0 ifrs/2024 Components Of Equity= Issued Capital;
0001410578-25-001369 20241231 Equity -1403796000.0000 EUR 0 ifrs/2024 Components Of Equity= Retained Earnings;
0001410578-25-001369 20250331 Equity 2075624000.0000 EUR 0 ifrs/2024 Components Of Equity= Capital Reserve;
0001410578-25-001369 20240331 Income Taxes Paid Classified As Operating Activities 918000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Income Taxes Paid Classified As Operating Activities 953000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes -43196000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Interest Paid Classified As Operating Activities 574000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Noncurrent Liabilities 34289000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Other Comprehensive Income -56000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20241231 Retained Earnings -1403796000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Revenue From Contracts With Customers 3478000.0000 EUR 1 ifrs/2024 Geographical Areas= C H; Major Customers= Crispr;
0001410578-25-001369 20240331 Revenue From Contracts With Customers 1940000.0000 EUR 1 ifrs/2024 Products And Services= Ifrs Product; Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred At Point In Time;
0001410578-25-001369 20250331 Rightofuse Assets 38082000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Settlement Of Share Based Payment Awards Amount 38000.0000 EUR 1 0001410578-25-001369 Components Of Equity= Issued Capital;
0001410578-25-000692 20221231 Equity -139000.0000 EUR 0 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001410578-25-000692 20231231 Equity -67000.0000 EUR 0 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001410578-25-000692 20241231 Equity 26921000.0000 EUR 0 ifrs/2024 Components Of Equity= Issued Capital;
0001410578-25-000692 20241231 Equity -1403796000.0000 EUR 0 ifrs/2024 Components Of Equity= Retained Earnings;
0001410578-25-000692 20221231 Exercise Of Options Settlement Of Share Based Payment Awards Amount 14000.0000 EUR 4 0001410578-25-000692 Components Of Equity= Issued Capital;
0001410578-25-000692 20221231 Finance Costs 3707000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Finance Costs 2493000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Finance Income 16731000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Impairments Of Inventory And Prepayments 23670000.0000 EUR 4 0001410578-25-000692
0001410578-25-000692 20221231 Increase Decrease In Contingent Consideration Asset Liability -18978000.0000 EUR 4 ifrs/2024 Components Of Equity= Capital Reserve;
0001410578-25-000692 20221231 Increase Decrease In Contingent Consideration Asset Liability -103000.0000 EUR 4 ifrs/2024 Components Of Equity= Issued Capital;
0001410578-25-000692 20231231 Interest Paid Classified As Operating Activities 2375000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Issued Capital 26879000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Issue Of Equity 235840000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Liabilities 271308000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Miscellaneous Other Operating Income 9151000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Other Comprehensive Income -105000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Other Comprehensive Income 72000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Other Current Financial Assets 3622000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Other Current Liabilities 29545000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20200731 Proceeds From Issuing Shares 150000000.0000 EUR 0 ifrs/2024 Major Customers= Glaxosmithkline;
0001410578-25-000692 20221231 Profit Loss -249029000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Profit Loss Before Tax 190881000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Property Plant And Equipment 2200000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Cumulative Amortization And Impairment; Classes Of Property Plant And Equipment= Construction In Progress;
0001410578-25-000692 20231231 Property Plant And Equipment 274205000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount;
0001410578-25-000692 20241231 Property Plant And Equipment 20434000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Cumulative Amortization And Impairment; Classes Of Property Plant And Equipment= Technical Equipment And Machines And Other Equipment;
0001410578-25-000692 20241231 Retained Earnings -1403796000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Revenue From Contracts With Customers 1197000.0000 EUR 4 ifrs/2024 Counterparty Name= Genmab; Ifrs Type Of Arrangement= Collaboration And License Agreement;
0001410578-25-000692 20231231 Revenue From Contracts With Customers 8000.0000 EUR 4 ifrs/2024 Geographical Areas= Countries Other Than Belgium Netherlands And Switzerland; Major Customers= Other Customers;
0001410578-25-000692 20231231 Revenue From Contracts With Customers 11395000.0000 EUR 4 ifrs/2024 Products And Services= Research And Development Services; Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred Over Time;
0001410578-25-000692 20231231 Revenue From Contracts With Customers 11312000.0000 EUR 4 ifrs/2024 Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred At Point In Time;
0001410578-25-000692 20241231 Revenue From Contracts With Customers 519850000.0000 EUR 4 ifrs/2024 Geographical Areas= B E; Major Customers= Glaxosmithkline;
0001410578-25-000692 20241231 Revenue From Contracts With Customers 410000000.0000 EUR 4 ifrs/2024 Products And Services= Granting Of Ip Licenses; Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred At Point In Time;
0001410578-25-000692 20221231 Rightofuse Assets 275000.0000 EUR 0 ifrs/2024 Classes Of Assets= Vehicles;
0001410578-25-000692 20231231 Rightofuse Assets 319000.0000 EUR 0 ifrs/2024 Classes Of Assets= Vehicles;
0001410578-25-000692 20241231 Rightofuse Assets 267000.0000 EUR 0 ifrs/2024 Classes Of Assets= Vehicles;
0001410578-25-000692 20241231 Trade And Other Current Payables 17272000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Diluted Earnings Loss Per Share 0.7200 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Equity 23400000.0000 EUR 0 ifrs/2024 Components Of Equity= Issued Capital;
0001410578-25-000692 20241231 Equity 2073444000.0000 EUR 0 ifrs/2024 Components Of Equity= Capital Reserve;
0001410578-25-000692 20231231 Accumulated Other Comprehensive Income -67000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss 2466000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Adjustments For Increase Decrease In Trade And Other Payables -140583000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Adjustments For Losses Gains On Disposal Of Noncurrent Assets 11981000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Adjustments Transfer To Asset Held For Sale 6711000.0000 EUR 4 0001410578-25-000692
0001410578-25-000692 20231231 Cash And Cash Equivalents 402452000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20221231 Comprehensive Income -249134000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Comprehensive Income 105000.0000 EUR 4 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001410578-25-000692 20241231 Current Liabilities 72348000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Deferred Tax Liabilities 3439000.0000 EUR 0 ifrs/2024 Temporary Difference Unused Tax Losses And Unused Tax Credits= Property Plant And Equipment;
0001410578-25-000692 20231231 Depreciation And Amortisation Expense 23386000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Depreciation And Amortisation Expense 18809000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Depreciation And Amortisation Expense 7814000.0000 EUR 4 ifrs/2024 Attribution Of Expenses By Nature To Their Function= Ifrs General And Administrative Expense;
0001410578-25-000692 20231231 General And Administrative Expense 91758000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Impairments Of Inventory And Prepayments 80021000.0000 EUR 4 0001410578-25-000692
0001410578-25-000692 20221231 Income Taxes Paid Classified As Operating Activities 128000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes -316503000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Increase Decrease In Contingent Consideration Asset Liability -19081000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Interest Received Classified As Operating Activities 15852000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Issue Of Equity 66381000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Miscellaneous Other Operating Expense 33415000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Noncurrent Assets 309868000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Noncurrent Assets 276412000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Other Comprehensive Income 72000.0000 EUR 4 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001410578-25-000692 20241231 Other Noncurrent Assets 1514000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20221231 Property Plant And Equipment 12617000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Cumulative Amortization And Impairment; Classes Of Property Plant And Equipment= Technical Equipment And Machines And Other Equipment;
0001410578-25-000692 20221231 Property Plant And Equipment 227509000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount;
0001410578-25-000692 20221231 Property Plant And Equipment 138457000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Construction In Progress;
0001410578-25-000692 20231231 Property Plant And Equipment 27537000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Buildings;
0001410578-25-000692 20241231 Property Plant And Equipment 204946000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Property Plant And Equipment 78532000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Cumulative Amortization And Impairment;
0001410578-25-000692 20241231 Purchase Of Intangible Assets Classified As Investing Activities 4129000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Research And Development Expense 115724000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Research And Development Expense 153034000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Revenue From Contracts With Customers 3370000.0000 EUR 4 ifrs/2024 Counterparty Name= Crispr Therapeutics;
0001410578-25-000692 20221231 Revenue From Contracts With Customers 20884000.0000 EUR 4 ifrs/2024 Counterparty Name= Glaxosmithkline; Ifrs Type Of Arrangement= Glaxosmithkline Covid Agreement;
0001410578-25-000692 20231231 Revenue From Contracts With Customers 42446000.0000 EUR 4 ifrs/2024 Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred Over Time;
0001410578-25-000692 20241231 Revenue From Contracts With Customers 12947000.0000 EUR 4 ifrs/2024 Counterparty Name= Crispr Therapeutics;
0001410578-25-000692 20241231 Revenue From Contracts With Customers 109724000.0000 EUR 4 ifrs/2024 Products And Services= Research And Development Services Combined With Ip License; Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred Over Time;
0001410578-25-000692 20231231 Rightofuse Assets 41843000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Rightofuse Assets 37842000.0000 EUR 0 ifrs/2024 Classes Of Assets= Land And Buildings;
0001410578-25-000692 20241231 Rightofuse Assets 1598000.0000 EUR 0 ifrs/2024 Classes Of Assets= Other Property Plant And Equipment;
0001410578-25-000692 20221231 Share Based Payment Expense Incl. Deferred Taxes 7539000.0000 EUR 4 0001410578-25-000692
0001410578-25-000692 20231231 Adjustments For Decrease Increase In Inventories -47940000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Adjustments For Increase Decrease In Provisions -25842000.0000 EUR 4 0001410578-25-000692
0001410578-25-000692 20231231 Adjustments For Increase Decrease In Trade And Other Payables -30099000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Adjustments For Losses Gains On Disposal Of Noncurrent Assets 646000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Basic Earnings Loss Per Share 0.7200 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Capital Reserve 2056110000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20221231 Cash And Cash Equivalents 495797000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Cash And Cash Equivalents 481748000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20221231 Cash Flows From Used In Financing Activities 63173000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Cash Flows From Used In Investing Activities -55200000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Cost Of Sales 183993000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Current Provisions 1956000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Current Tax Assets Current 5201000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Deferred Tax Liabilities 6583000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Deferred Tax Liabilities 67000.0000 EUR 0 ifrs/2024 Temporary Difference Unused Tax Losses And Unused Tax Credits= Ifrs Other Noncurrent Liabilities;
0001410578-25-000692 20231231 Deferred Tax Liabilities 142000.0000 EUR 0 ifrs/2024 Temporary Difference Unused Tax Losses And Unused Tax Credits= Trade And Other Payables;
0001410578-25-000692 20241231 Deferred Tax Liabilities 244000.0000 EUR 0 ifrs/2024 Temporary Difference Unused Tax Losses And Unused Tax Credits= Ifrs Other Liabilities;
0001410578-25-000692 20241231 Deferred Tax Liabilities 621000.0000 EUR 0 ifrs/2024 Temporary Difference Unused Tax Losses And Unused Tax Credits= Trade And Other Payables;
0001410578-25-000692 20241231 Deferred Tax Liabilities 840000.0000 EUR 0 ifrs/2024 Temporary Difference Unused Tax Losses And Unused Tax Credits= Trade Receivables;
0001410578-25-000692 20231231 Depreciation And Amortisation Expense 8539000.0000 EUR 4 ifrs/2024 Attribution Of Expenses By Nature To Their Function= Ifrs Research And Development Expense;
0001410578-25-001369 20240331 Adjustments For Gain Loss On Disposals Property Plant And Equipment -131000.0000 EUR 1 ifrs/2024
0001410578-25-000692 20231231 Adjustments For Decrease Increase In Trade Receivables Contract Assets Assets Held For Sale And Other Assets 9749000.0000 EUR 4 0001410578-25-000692
0001410578-25-000692 20241231 Adjustments For Finance Costs 829000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Assets 788249000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20221231 Basic Earnings Loss Per Share -1.3200 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Cash Flows From Used In Financing Activities -5114000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Cash Flows From Used In Investing Activities -18444000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities 277000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Current Tax Liabilities 654000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Deferred Tax Liabilities 12000.0000 EUR 0 ifrs/2024 Temporary Difference Unused Tax Losses And Unused Tax Credits= Ifrs Cash And Cash Equivalents;
0001410578-25-000692 20231231 Deferred Tax Liabilities 137000.0000 EUR 0 ifrs/2024 Temporary Difference Unused Tax Losses And Unused Tax Credits= Ifrs Other Liabilities;
0001410578-25-000692 20231231 Deferred Tax Liabilities 1224000.0000 EUR 0 ifrs/2024 Temporary Difference Unused Tax Losses And Unused Tax Credits= Intangible Assets;
0001410578-25-000692 20241231 Deferred Tax Liabilities 19597000.0000 EUR 0 ifrs/2024 Temporary Difference Unused Tax Losses And Unused Tax Credits= Deferred Tax Assets And Deferred Tax Liability Netting;
0001410578-25-000692 20221231 Depreciation And Amortisation Expense 11360000.0000 EUR 4 ifrs/2024 Attribution Of Expenses By Nature To Their Function= Ifrs General And Administrative Expense;
0001410578-25-000692 20231231 Diluted Earnings Loss Per Share -1.1800 EUR 4 ifrs/2024
0001410578-25-000692 20211231 Equity 22454000.0000 EUR 0 ifrs/2024 Components Of Equity= Issued Capital;
0001410578-25-000692 20211231 Equity -34000.0000 EUR 0 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001410578-25-000692 20221231 Equity 1817287000.0000 EUR 0 ifrs/2024 Components Of Equity= Capital Reserve;
0001410578-25-000692 20231231 Equity 516941000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20221231 Finance Income 4009000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 General And Administrative Expense 104178000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 78293000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Issue Of Equity 3453000.0000 EUR 4 ifrs/2024 Components Of Equity= Issued Capital;
0001410578-25-000692 20221231 Miscellaneous Other Operating Income 37932000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners 1597000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Noncurrent Contract Liabilities 48100000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Noncurrent Liabilities 33871000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Other Comprehensive Income Net Of Tax Exchange Differences On Translation 105000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Other Current Financial Assets 2661000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20221231 Property Plant And Equipment 7415000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Cumulative Amortization And Impairment; Classes Of Property Plant And Equipment= Other Property Plant And Equipment;
0001410578-25-000692 20221231 Property Plant And Equipment 137631000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Construction In Progress;
0001410578-25-000692 20231231 Property Plant And Equipment 37424000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Cumulative Amortization And Impairment;
0001410578-25-000692 20231231 Property Plant And Equipment 40669000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Technical Equipment And Machines And Other Equipment;
0001410578-25-000692 20221231 Revenue From Contracts With Customers 1787000.0000 EUR 4 ifrs/2024 Counterparty Name= Genmab; Ifrs Type Of Arrangement= Collaboration And License Agreement;
0001410578-25-000692 20231231 Revenue From Contracts With Customers 31051000.0000 EUR 4 ifrs/2024 Products And Services= Research And Development Services Combined With Ip License; Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred Over Time;
0001410578-25-000692 20241231 Revenue From Contracts With Customers 6173000.0000 EUR 4 ifrs/2024 Products And Services= Ifrs Product; Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred At Point In Time;
0001410578-25-000692 20241231 Revenue From Contracts With Customers 119007000.0000 EUR 4 ifrs/2024 Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred Over Time;
0001410578-25-000692 20221231 Rightofuse Assets 2303000.0000 EUR 0 ifrs/2024 Classes Of Assets= Other Property Plant And Equipment;
0001410578-25-000692 20231231 Sales And Marketing Expense 3912000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Settlement Of Share Based Payment Awards Amount 1481000.0000 EUR 4 0001410578-25-000692 Components Of Equity= Treasury Shares;
0001410578-25-000692 20241231 Share Based Payment Expense Incl. Deferred Taxes 4121000.0000 EUR 4 0001410578-25-000692
0001410578-25-000692 20241231 Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss 35298000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Adjustments For Losses Gains On Disposal Of Noncurrent Assets 3477000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Adjustments For Sharebased Payments 9185000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Adjustments For Sharebased Payments 7697000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Cash Flows From Used In Financing Activities 230893000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Cash Flows From Used In Operating Activities -286177000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Comprehensive Income -260095000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Cost Of Sales 124366000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Current Assets 526414000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Current Contract Assets 2764000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Current Contract Liabilities 44580000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Current Provisions 37400000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Current Tax Liabilities 18254000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Current Trade Receivables 14326000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Current Trade Receivables 14077000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20221231 Deferred Tax Liabilities 56000.0000 EUR 0 ifrs/2024 Categories Of Related Parties= Subsidiaries;
0001410578-25-000692 20231231 Deferred Tax Liabilities 10490000.0000 EUR 0 ifrs/2024 Temporary Difference Unused Tax Losses And Unused Tax Credits= Deferred Tax Assets And Deferred Tax Liability Netting;
0001410578-25-000692 20241231 Deferred Tax Liabilities 815000.0000 EUR 0 ifrs/2024 Temporary Difference Unused Tax Losses And Unused Tax Credits= Ifrsprepaid Expenses And Other Assets;
0001410578-25-000692 20241231 Deferred Tax Liabilities 4141000.0000 EUR 0 ifrs/2024 Temporary Difference Unused Tax Losses And Unused Tax Credits= Property Plant And Equipment;
0001410578-25-000692 20231231 Depreciation And Amortisation Expense 4850000.0000 EUR 4 ifrs/2024 Attribution Of Expenses By Nature To Their Function= Cost Of Sales;
0001410578-25-000692 20241231 Effect Of Exchange Rate Changes On Cash And Cash Equivalents 1003000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Equity -1481000.0000 EUR 0 ifrs/2024 Components Of Equity= Treasury Shares;
0001410578-25-000692 20231231 Equity 2056110000.0000 EUR 0 ifrs/2024 Components Of Equity= Capital Reserve;
0001410578-25-000692 20221231 Exercise Of Options Settlement Of Share Based Payment Awards Amount 910000.0000 EUR 4 0001410578-25-000692
0001410578-25-000692 20241231 Finance Income 14028000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Interest Received Classified As Operating Activities 1790000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Inventories 541000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Miscellaneous Other Operating Expense 1356000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Miscellaneous Other Operating Income 8917000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Net Deferred Tax Assets 1194000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Noncurrent Lease Liabilities 33644000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Other Current Liabilities 50717000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20221231 Payments Of Lease Liabilities Classified As Financing Activities 4221000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Payments Of Lease Liabilities Classified As Financing Activities 5193000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Profit Loss -260167000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Profit Loss 162186000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Property Plant And Equipment 12552000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Other Property Plant And Equipment;
0001410578-25-000692 20221231 Property Plant And Equipment 50033000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Technical Equipment And Machines And Other Equipment;
0001410578-25-000692 20221231 Property Plant And Equipment 17757000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Buildings;
0001410578-25-000692 20231231 Property Plant And Equipment 14272000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Cumulative Amortization And Impairment; Classes Of Property Plant And Equipment= Technical Equipment And Machines And Other Equipment;
0001410578-25-000692 20231231 Property Plant And Equipment 178990000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Construction In Progress;
0001410578-25-000692 20241231 Property Plant And Equipment 183645000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Construction In Progress;
0001410578-25-000692 20241231 Property Plant And Equipment 39178000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Technical Equipment And Machines And Other Equipment;
0001410578-25-000692 20221231 Purchase Of Property Plant And Equipment Classified As Investing Activities 88023000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Purchase Of Property Plant And Equipment Classified As Investing Activities 52320000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Revenue From Contracts With Customers 19571000.0000 EUR 4 ifrs/2024 Products And Services= Research And Development Services; Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred Over Time;
0001410578-25-000692 20221231 Revenue From Contracts With Customers 44787000.0000 EUR 4 ifrs/2024 Products And Services= Research And Development Services Combined With Ip License; Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred Over Time;
0001410578-25-000692 20231231 Revenue From Contracts With Customers 10530000.0000 EUR 4 ifrs/2024 Counterparty Name= Glaxosmithkline; Ifrs Type Of Arrangement= Glaxosmithkline Covid Agreement;
0001410578-25-000692 20241231 Revenue From Contracts With Customers 2383000.0000 EUR 4 ifrs/2024 Counterparty Name= Genmab; Ifrs Type Of Arrangement= Collaboration And License Agreement;
0001410578-25-000692 20241231 Revenue From Contracts With Customers 2383000.0000 EUR 4 ifrs/2024 Geographical Areas= N L; Major Customers= Genmab;
0001410578-25-000692 20241231 Revenue From Contracts With Customers 9283000.0000 EUR 4 ifrs/2024 Products And Services= Research And Development Services; Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred Over Time;
0001410578-25-000692 20221231 Rightofuse Assets 43761000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Tax Benefit Arising From Previously Unrecognised Tax Loss Tax Credit Or Temporary Difference Of Prior Period Used To Reduce Current Tax Expense 13386000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Adjustments For Decrease Increase In Inventories 590000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Adjustments For Decrease Increase In Trade Receivables Contract Assets Assets Held For Sale And Other Assets 18470000.0000 EUR 4 0001410578-25-000692
0001410578-25-000692 20241231 Adjustments For Decrease Increase In Trade Receivables Contract Assets Assets Held For Sale And Other Assets 11474000.0000 EUR 4 0001410578-25-000692
0001410578-25-000692 20221231 Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss 6594000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Adjustments For Increase Decrease In Trade And Other Payables -96182000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Capital Reserve 2073444000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Cash Flows From Used In Operating Activities -267887000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Comprehensive Income -105000.0000 EUR 4 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001410578-25-000692 20231231 Comprehensive Income 72000.0000 EUR 4 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001410578-25-000692 20231231 Comprehensive Income -260167000.0000 EUR 4 ifrs/2024 Components Of Equity= Retained Earnings;
0001410578-25-000692 20231231 Current Lease Liabilities 5005000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Current Prepayments And Other Current Assets 23763000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Current Prepayments And Other Current Assets 16271000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Current Tax Assets Current 5794000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Deferred Tax Liabilities 227000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20241231 Deferred Tax Liabilities 122000.0000 EUR 0 ifrs/2024 Categories Of Related Parties= Subsidiaries;
0001410578-25-000692 20241231 Deferred Tax Liabilities 238000.0000 EUR 0 ifrs/2024 Temporary Difference Unused Tax Losses And Unused Tax Credits= Ifrs Other Noncurrent Liabilities;
0001410578-25-000692 20221231 Depreciation And Amortisation Expense 8650000.0000 EUR 4 ifrs/2024 Attribution Of Expenses By Nature To Their Function= Ifrs Research And Development Expense;
0001410578-25-000692 20241231 Depreciation And Amortisation Expense 3201000.0000 EUR 4 ifrs/2024 Attribution Of Expenses By Nature To Their Function= Cost Of Sales;
0001410578-25-000692 20241231 Depreciation And Amortisation Expense 11596000.0000 EUR 4 ifrs/2024 Attribution Of Expenses By Nature To Their Function= Ifrs Research And Development Expense;
0001410578-25-000692 20221231 Effect Of Exchange Rate Changes On Cash And Cash Equivalents 836000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Effect Of Exchange Rate Changes On Cash And Cash Equivalents -1151000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20211231 Equity 688476000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20211231 Equity 1728658000.0000 EUR 0 ifrs/2024 Components Of Equity= Capital Reserve;
0001410578-25-000692 20221231 Equity 533253000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Equity -1565981000.0000 EUR 0 ifrs/2024 Components Of Equity= Retained Earnings;
0001410578-25-000692 20241231 Equity 39000.0000 EUR 0 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001410578-25-000692 20221231 Exercise Of Options Settlement Of Share Based Payment Awards Amount -3440000.0000 EUR 4 0001410578-25-000692 Components Of Equity= Capital Reserve;
0001410578-25-000692 20221231 Exercise Of Options Settlement Of Share Based Payment Awards Amount 4336000.0000 EUR 4 0001410578-25-000692 Components Of Equity= Treasury Shares;
0001410578-25-000692 20231231 Income Taxes Paid Classified As Operating Activities 3891000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Income Taxes Paid Classified As Operating Activities 3154000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Interest Received Classified As Operating Activities 11067000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Issue Of Equity 65552000.0000 EUR 4 ifrs/2024 Components Of Equity= Capital Reserve;
0001410578-25-000692 20241231 Net Deferred Tax Assets 5092000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners 2419000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Noncurrent Lease Liabilities 36819000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Noncurrent Liabilities 84919000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20221231 Other Comprehensive Income -105000.0000 EUR 4 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001410578-25-000692 20231231 Profit Loss Before Tax -259969000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Profit Loss From Operating Activities -274207000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Property Plant And Equipment 29568000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Cumulative Amortization And Impairment;
0001410578-25-000692 20221231 Property Plant And Equipment 8710000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Cumulative Amortization And Impairment; Classes Of Property Plant And Equipment= Buildings;
0001410578-25-000692 20221231 Property Plant And Equipment 5137000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Other Property Plant And Equipment;
0001410578-25-000692 20231231 Property Plant And Equipment 14623000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Buildings;
0001410578-25-000692 20241231 Property Plant And Equipment 14846000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Cumulative Amortization And Impairment; Classes Of Property Plant And Equipment= Buildings;
0001410578-25-000692 20241231 Property Plant And Equipment 28195000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Buildings;
0001410578-25-000692 20241231 Property Plant And Equipment 12026000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Other Property Plant And Equipment;
0001410578-25-000692 20241231 Property Plant And Equipment 13349000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Buildings;
0001410578-25-000692 20241231 Property Plant And Equipment 144581000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Company Owned Gmp Iv Facility;
0001410578-25-000692 20241231 Property Plant And Equipment 149209000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Construction In Progress;
0001410578-25-000692 20241231 Purchase Of Property Plant And Equipment Classified As Investing Activities 14315000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Research And Development Expense 62550000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Revenue From Contracts With Customers 5425000.0000 EUR 4 ifrs/2024 Geographical Areas= C H; Major Customers= Crispr;
0001410578-25-000692 20241031 Revenue From Contracts With Customers 1830000.0000 EUR 0 ifrs/2024 Counterparty Name= Glaxosmithkline; Ifrs Type Of Arrangement= Transitional Service Agreement;
0001410578-25-000692 20231231 Rightofuse Assets 1950000.0000 EUR 0 ifrs/2024 Classes Of Assets= Other Property Plant And Equipment;
0001410578-25-000692 20241231 Settlement Of Share Based Payment Awards Amount -173000.0000 EUR 4 0001410578-25-000692 Components Of Equity= Capital Reserve;
0001410578-25-000692 20241231 Settlement Of Share Based Payment Awards Amount 42000.0000 EUR 4 0001410578-25-000692 Components Of Equity= Issued Capital;
0001410578-25-000692 20221231 Share Based Payment Expense Incl. Deferred Taxes 7539000.0000 EUR 4 0001410578-25-000692 Components Of Equity= Capital Reserve;
0001410578-25-000692 20231231 Trade And Other Current Payables 48033000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20241231 Accumulated Other Comprehensive Income 39000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Assets 742267000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Cash Flows From Used In Investing Activities -5088000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Cash Flows From Used In Investing Activities -511000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Cash Flows From Used In Operating Activities -96554000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Comprehensive Income -56000.0000 EUR 1 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001410578-25-001369 20250331 Current Assets 469100000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Current Lease Liabilities 5198000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20241231 Current Prepayments And Other Current Assets 16271000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Depreciation And Amortisation Expense 4577000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Depreciation And Amortisation Expense 2179000.0000 EUR 1 ifrs/2024 Attribution Of Expenses By Nature To Their Function= Ifrs General And Administrative Expense;
0001410578-25-001369 20250331 Diluted Earnings Loss Per Share -0.2300 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Miscellaneous Other Operating Income 4132000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20241231 Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners 1597000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners 1529000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Other Noncurrent Liabilities 1880000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Retained Earnings -1455880000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Tax Benefit Arising From Previously Unrecognised Tax Loss Tax Credit Or Temporary Difference Of Prior Period Used To Reduce Current Tax Expense 1122000.0000 EUR 1 ifrs/2024 Components Of Equity= Capital Reserve;
0001410578-25-001369 20250331 Trade And Other Current Payables 9428000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Adjustments For Decrease Increase In Trade Receivables Contract Assets Assets Held For Sale And Other Assets 1329000.0000 EUR 1 0001410578-25-001369
0001410578-25-001369 20250331 Adjustments For Decrease Increase In Trade Receivables Contract Assets Assets Held For Sale And Other Assets 14729000.0000 EUR 1 0001410578-25-001369
0001410578-25-001369 20250331 Adjustments For Gain Loss On Disposals Property Plant And Equipment -265000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Adjustments For Increase Decrease In Trade And Other Payables -8815000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Comprehensive Income -52197000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Current Provisions 1856000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20241231 Current Tax Assets Current 5794000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Current Tax Liabilities 18415000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Effect Of Exchange Rate Changes On Cash And Cash Equivalents 466000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20231231 Equity -1565981000.0000 EUR 0 ifrs/2024 Components Of Equity= Retained Earnings;
0001410578-25-001369 20240331 Equity 2056654000.0000 EUR 0 ifrs/2024 Components Of Equity= Capital Reserve;
0001410578-25-001369 20241231 Equity 696608000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Equity 27019000.0000 EUR 0 ifrs/2024 Components Of Equity= Issued Capital;
0001410578-25-001369 20241231 Intangible Assets And Goodwill 25155000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Intangible Assets And Goodwill 24729000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20241231 Issued Capital 26921000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Miscellaneous Other Operating Income 528000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Other Comprehensive Income Net Of Tax Exchange Differences On Translation -113000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Other Current Financial Assets 3756000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Proceed From Issuing Other Equity Instrument Or Exercise Of Options 95000.0000 EUR 1 0001410578-25-001369
0001410578-25-001369 20240331 Profit Loss -70553000.0000 EUR 1 ifrs/2024 Components Of Equity= Retained Earnings;
0001410578-25-001369 20250331 Profit Loss -52084000.0000 EUR 1 ifrs/2024 Components Of Equity= Retained Earnings;
0001410578-25-001369 20240331 Revenue From Contracts With Customers 8895000.0000 EUR 1 ifrs/2024 Ifrs Type Of Arrangement= Collaboration Agreement For Research Development Manufacturing And Commercialization Of Mrna Based Vaccines; Major Customers= Glaxosmithkline;
0001410578-25-001369 20240331 Revenue From Contracts With Customers 1940000.0000 EUR 1 ifrs/2024 Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred At Point In Time;
0001410578-25-001369 20250331 Revenue From Contracts With Customers 306000.0000 EUR 1 ifrs/2024 Geographical Areas= B E; Major Customers= Glaxosmithkline;
0001410578-25-001369 20250331 Revenue From Contracts With Customers 680000.0000 EUR 1 ifrs/2024 Products And Services= Research And Development Services; Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred Over Time;
0001410578-25-001369 20241231 Rightofuse Assets 39706000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Settlement Of Share Based Payment Awards Amount 56000.0000 EUR 1 0001410578-25-001369 Components Of Equity= Capital Reserve;
0001410578-25-001369 20240331 Share Based Payment Expense Incl. Deferred Taxes 487000.0000 EUR 1 0001410578-25-001369
0001410578-25-001369 20240331 Share Based Payment Expense Incl. Deferred Taxes 487000.0000 EUR 1 0001410578-25-001369 Components Of Equity= Capital Reserve;
0001410578-25-001369 20240331 Adjustments For Finance Income 3771000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Adjustments For Sharebased Payments 487000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Basic Earnings Loss Per Share -0.3100 EUR 1 ifrs/2024
0001410578-25-001369 20241231 Capital Reserve 2073444000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20241231 Current Assets 526414000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Diluted Earnings Loss Per Share -0.3100 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Effect Of Exchange Rate Changes On Cash And Cash Equivalents -220000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Equity 26917000.0000 EUR 0 ifrs/2024 Components Of Equity= Issued Capital;
0001410578-25-001369 20241231 Equity 39000.0000 EUR 0 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001410578-25-001369 20250331 Equity 646689000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Finance Costs 333000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20241231 Net Deferred Tax Assets 5092000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20241231 Noncurrent Lease Liabilities 33644000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Other Comprehensive Income -113000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Other Comprehensive Income Net Of Tax Exchange Differences On Translation -56000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20241231 Other Noncurrent Assets 1514000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Payments Of Lease Liabilities Classified As Financing Activities 1219000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Profit Loss -70553000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Profit Loss Before Tax -51655000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Purchase Of Intangible Assets Classified As Investing Activities 27000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Research And Development Expense 27825000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Revenue From Contracts With Customers 2741000.0000 EUR 1 ifrs/2024 Products And Services= Research And Development Services; Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred Over Time;
0001410578-25-001369 20250331 Revenue From Contracts With Customers 893000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Sales And Marketing Expense 963000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Adjustments For Finance Costs 340000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Adjustments For Finance Income 3405000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Adjustments For Increase Decrease In Trade And Other Payables -46335000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Adjustments For Sharebased Payments 1156000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20241231 Assets 802827000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Cash And Cash Equivalents 300152000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Cash Flows From Used In Operating Activities -41374000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Comprehensive Income -70553000.0000 EUR 1 ifrs/2024 Components Of Equity= Retained Earnings;
0001410578-25-001369 20250331 Current Contract Assets 2092000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Depreciation And Amortisation Expense 1840000.0000 EUR 1 ifrs/2024 Attribution Of Expenses By Nature To Their Function= Ifrs Research And Development Expense;
0001410578-25-001369 20231231 Equity -67000.0000 EUR 0 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001410578-25-001369 20240331 Equity 446913000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Equity And Liabilities 742267000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Finance Income 3405000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Interest Paid Classified As Operating Activities 589000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Liabilities 95578000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Net Deferred Tax Assets 5938000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Noncurrent Assets 273167000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Other Comprehensive Income -113000.0000 EUR 1 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001410578-25-001369 20250331 Property Plant And Equipment 202904000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Revenue From Contracts With Customers 8895000.0000 EUR 1 ifrs/2024 Geographical Areas= B E; Major Customers= Glaxosmithkline;
0001410578-25-001369 20250331 Revenue From Contracts With Customers 586000.0000 EUR 1 ifrs/2024 Geographical Areas= C H; Major Customers= Crispr;
0001410578-25-001369 20250331 Revenue From Contracts With Customers 6000.0000 EUR 1 ifrs/2024 Products And Services= Ifrs Product; Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred At Point In Time;
0001410578-25-001369 20250331 Basic Earnings Loss Per Share -0.2300 EUR 1 ifrs/2024
0001410578-25-001369 20241231 Cash And Cash Equivalents 481748000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Cost Of Sales 875000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20241231 Current Contract Assets 2764000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Depreciation And Amortisation Expense 2647000.0000 EUR 1 ifrs/2024 Attribution Of Expenses By Nature To Their Function= Ifrs Research And Development Expense;
0001410578-25-001369 20250331 Equity -74000.0000 EUR 0 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001410578-25-001369 20240331 Finance Costs 340000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 General And Administrative Expense 19119000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Income Tax Expense Continuing Operations 666000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes -102766000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Interest Received Classified As Operating Activities 2136000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20241231 Noncurrent Assets 276412000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20241231 Noncurrent Liabilities 33871000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Profit Loss Before Tax -69887000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Profit Loss From Operating Activities -73317000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20241231 Property Plant And Equipment 204946000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Purchase Of Property Plant And Equipment Classified As Investing Activities 5074000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Revenue From Contracts With Customers 207000.0000 EUR 1 ifrs/2024 Products And Services= Research And Development Services Combined With Ip License; Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred Over Time;
0001410578-25-001369 20240331 Settlement Of Share Based Payment Awards Amount 95000.0000 EUR 1 0001410578-25-001369
0001410578-25-001369 20250331 Share Based Payment Expense Incl. Deferred Taxes 1156000.0000 EUR 1 0001410578-25-001369 Components Of Equity= Capital Reserve;
0001410578-25-001369 20240331 Adjustments For Decrease Increase In Inventories -1406000.0000 EUR 1 ifrs/2024
0001410578-25-000692 20221231 Adjustments For Finance Costs 3707000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Adjustments For Finance Costs 2493000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Adjustments For Finance Income 4009000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Adjustments For Finance Income 16731000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Adjustments For Finance Income 14028000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Adjustments For Increase Decrease In Provisions -35444000.0000 EUR 4 0001410578-25-000692
0001410578-25-000692 20241231 Cash Flows From Used In Operating Activities 101851000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Comprehensive Income -249029000.0000 EUR 4 ifrs/2024 Components Of Equity= Retained Earnings;
0001410578-25-000692 20241231 Cost Of Sales 105829000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Current Provisions 1956000.0000 EUR 0 ifrs/2024 Classes Of Provisions= Legal Proceedings Provision;
0001410578-25-000692 20231231 Deferred Tax Liabilities 8000.0000 EUR 0 ifrs/2024 Categories Of Related Parties= Subsidiaries;
0001410578-25-000692 20241231 Deferred Tax Liabilities 11633000.0000 EUR 0 ifrs/2024 Temporary Difference Unused Tax Losses And Unused Tax Credits= Rightofuse Assets;
0001410578-25-000692 20221231 Depreciation And Amortisation Expense 26641000.0000 EUR 4 ifrs/2024 Attribution Of Expenses By Nature To Their Function= Operative Expenses;
0001410578-25-000692 20221231 Diluted Earnings Loss Per Share -1.3200 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Equity 26879000.0000 EUR 0 ifrs/2024 Components Of Equity= Issued Capital;
0001410578-25-000692 20241231 Equity And Liabilities 802827000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Impairments Of Inventory And Prepayments 47129000.0000 EUR 4 0001410578-25-000692
0001410578-25-000692 20221231 Income Tax Expense Continuing Operations -126000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Income Tax Expense Continuing Operations 198000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes -92194000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Intangible Assets And Goodwill 25155000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20221231 Interest Paid Classified As Operating Activities 4606000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Issued Capital 26921000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20231231 Issue Of Equity 232387000.0000 EUR 4 ifrs/2024 Components Of Equity= Capital Reserve;
0001410578-25-000692 20241231 Liabilities 106219000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20221231 Miscellaneous Other Operating Expense 1271000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Other Comprehensive Income 105000.0000 EUR 4 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001410578-25-000692 20221231 Other Comprehensive Income Net Of Tax Exchange Differences On Translation -105000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Other Comprehensive Income Net Of Tax Exchange Differences On Translation 72000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Proceeds From Issuing Shares 235840000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Profit Loss -260167000.0000 EUR 4 ifrs/2024 Components Of Equity= Retained Earnings;
0001410578-25-000692 20221231 Profit Loss Before Tax -249155000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20221231 Property Plant And Equipment 826000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Cumulative Amortization And Impairment; Classes Of Property Plant And Equipment= Construction In Progress;
0001410578-25-000692 20231231 Property Plant And Equipment 12736000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Other Property Plant And Equipment;
0001410578-25-000692 20241231 Property Plant And Equipment 8817000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Cumulative Amortization And Impairment; Classes Of Property Plant And Equipment= Other Property Plant And Equipment;
0001410578-25-000692 20221231 Revenue From Contracts With Customers 41379000.0000 EUR 4 ifrs/2024 Counterparty Name= Glaxosmithkline; Ifrs Type Of Arrangement= Collaboration Agreement For Research Development Manufacturing And Commercialization Of Mrna Based Vaccines;
0001410578-25-000692 20221231 Revenue From Contracts With Customers 62263000.0000 EUR 4 ifrs/2024 Geographical Areas= B E; Major Customers= Glaxosmithkline;
0001410578-25-000692 20221231 Revenue From Contracts With Customers 3062000.0000 EUR 4 ifrs/2024 Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred At Point In Time;
0001410578-25-000692 20221231 Revenue From Contracts With Customers 64358000.0000 EUR 4 ifrs/2024 Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred Over Time;
0001410578-25-000692 20231231 Revenue From Contracts With Customers 53758000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Revenue From Contracts With Customers 27740000.0000 EUR 4 ifrs/2024 Counterparty Name= Glaxosmithkline; Ifrs Type Of Arrangement= Collaboration Agreement For Research Development Manufacturing And Commercialization Of Mrna Based Vaccines;
0001410578-25-000692 20231231 Revenue From Contracts With Customers 47128000.0000 EUR 4 ifrs/2024 Geographical Areas= B E; Major Customers= Glaxosmithkline;
0001410578-25-000692 20241231 Revenue From Contracts With Customers 535180000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20241231 Revenue From Contracts With Customers 88316000.0000 EUR 4 ifrs/2024 Counterparty Name= Glaxosmithkline; Ifrs Type Of Arrangement= Collaboration Agreement For Research Development Manufacturing And Commercialization Of Mrna Based Vaccines;
0001410578-25-000692 20241231 Rightofuse Assets 39706000.0000 EUR 0 ifrs/2024
0001410578-25-000692 20221231 Sales And Marketing Expense 2817000.0000 EUR 4 ifrs/2024
0001410578-25-000692 20231231 Settlement Of Share Based Payment Awards Amount 246000.0000 EUR 4 0001410578-25-000692
0001410578-25-000692 20231231 Settlement Of Share Based Payment Awards Amount -1261000.0000 EUR 4 0001410578-25-000692 Components Of Equity= Capital Reserve;
0001410578-25-000692 20231231 Share Based Payment Expense Incl. Deferred Taxes 7697000.0000 EUR 4 0001410578-25-000692
0001410578-25-000692 20241231 Share Based Payment Expense Incl. Deferred Taxes 4121000.0000 EUR 4 0001410578-25-000692 Components Of Equity= Capital Reserve;
0001410578-25-000692 20241231 Tax Benefit Arising From Previously Unrecognised Tax Loss Tax Credit Or Temporary Difference Of Prior Period Used To Reduce Current Tax Expense 13386000.0000 EUR 4 ifrs/2024 Components Of Equity= Capital Reserve;
0001410578-25-001369 20250331 Adjustments For Provisions -100000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Cash Flows From Used In Financing Activities -1124000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20241231 Current Lease Liabilities 5321000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Current Prepayments And Other Current Assets 14179000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Current Tax Assets Current 6802000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Depreciation And Amortisation Expense 4867000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Equity -123000.0000 EUR 0 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001410578-25-001369 20250331 Equity -1455880000.0000 EUR 0 ifrs/2024 Components Of Equity= Retained Earnings;
0001410578-25-001369 20240331 Finance Income 3771000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 General And Administrative Expense 16409000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Income Tax Expense Continuing Operations 429000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20241231 Inventories 541000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Issued Capital 27019000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20240331 Miscellaneous Other Operating Expense 234000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Miscellaneous Other Operating Expense 307000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20241231 Other Current Financial Assets 3622000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20241231 Other Current Liabilities 29545000.0000 EUR 0 ifrs/2024
0001410578-25-001369 20250331 Payments Of Lease Liabilities Classified As Financing Activities 1312000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Profit Loss -52084000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Profit Loss From Operating Activities -54727000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Research And Development Expense 37593000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Revenue From Contracts With Customers 12373000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20240331 Revenue From Contracts With Customers 7692000.0000 EUR 1 ifrs/2024 Products And Services= Research And Development Services Combined With Ip License; Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred Over Time;
0001410578-25-001369 20240331 Revenue From Contracts With Customers 10433000.0000 EUR 1 ifrs/2024 Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred Over Time;
0001410578-25-001369 20250331 Revenue From Contracts With Customers 887000.0000 EUR 1 ifrs/2024 Timing Of Transfer Of Goods Or Services= Goods Or Services Transferred Over Time;
0001410578-25-001369 20240331 Sales And Marketing Expense 955000.0000 EUR 1 ifrs/2024
0001410578-25-001369 20250331 Settlement Of Share Based Payment Awards Amount -99000.0000 EUR 1 0001410578-25-001369 Components Of Equity= Capital Reserve;
0001410578-25-001369 20250331 Share Based Payment Expense Incl. Deferred Taxes 1156000.0000 EUR 1 0001410578-25-001369
0001410578-25-001369 20241231 Trade And Other Current Payables 17272000.0000 EUR 0 ifrs/2024

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
ddate The end date for the data value, rounded to the nearest month end.
qtrs The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value.
uom The unit of measure for the value.
segments Tags used to represent axis and member reporting.
coreg If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity.
value The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point.
footnote The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank.

Tags

tag version custom abstract datatype iord crdr tlabel doc
Income Taxes Paid Classified As Operating Activities ifrs/2024 0 0 monetary D C Income taxes paid, classified as operating activities The cash outflow for income taxes paid, classified as operating activities.
Accumulated Other Comprehensive Income ifrs/2024 0 0 monetary I C Accumulated other comprehensive income The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]
Adjustments For Decrease Increase In Inventories ifrs/2024 0 0 monetary D D Adjustments for decrease (increase) in inventories Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]
Cash And Cash Equivalents ifrs/2024 0 0 monetary I D Cash and cash equivalents The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]
Current Lease Liabilities ifrs/2024 0 0 monetary I C Current lease liabilities The amount of current lease liabilities. [Refer: Lease liabilities]
Depreciation And Amortisation Expense ifrs/2024 0 0 monetary D D Depreciation and amortisation expense The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.
Profit Loss Before Tax ifrs/2024 0 0 monetary D C Profit (loss) before tax The profit (loss) before tax expense or income. [Refer: Profit (loss)]
Purchase Of Property Plant And Equipment Classified As Investing Activities ifrs/2024 0 0 monetary D C Purchase of property, plant and equipment, classified as investing activities The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]
General And Administrative Expense ifrs/2024 0 0 monetary D D General and administrative expense The amount of expense relating to general and administrative activities of the entity.
Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes ifrs/2024 0 0 monetary D D Increase (decrease) in cash and cash equivalents before effect of exchange rate changes The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]
Retained Earnings ifrs/2024 0 0 monetary I C Retained earnings A component of equity representing the entity's cumulative undistributed earnings or deficit.
Tax Benefit Arising From Previously Unrecognised Tax Loss Tax Credit Or Temporary Difference Of Prior Period Used To Reduce Current Tax Expense ifrs/2024 0 0 monetary D C Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce current tax expense. [Refer: Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]
Adjustments For Provisions ifrs/2024 0 0 monetary D D Adjustments for provisions Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]
Equity And Liabilities ifrs/2024 0 0 monetary I C Equity and liabilities The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]
Inventories ifrs/2024 0 0 monetary I D Current inventories The amount of current inventories. [Refer: Inventories]
Proceeds From Issuing Shares ifrs/2024 0 0 monetary D D Proceeds from issuing shares The cash inflow from issuing shares.
Profit Loss From Operating Activities ifrs/2024 0 0 monetary D C Profit (loss) from operating activities The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]
Trade And Other Current Payables ifrs/2024 0 0 monetary I C Trade and other current payables The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]
Adjustments For Increase Decrease In Provisions 0001410578-25-000692 1 0 monetary D D Adjustments For Increase (Decrease) In Provisions Adjustments for increase (decrease) in provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.
Exercise Of Options Settlement Of Share Based Payment Awards Amount 0001410578-25-000692 1 0 monetary D C Exercise of Options Settlement Of Share Based Payment Awards Amount The amount of exercise of options or share based payment awards settled in cash.
Comprehensive Income ifrs/2024 0 0 monetary D C Comprehensive income The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.
Current Liabilities ifrs/2024 0 0 monetary I C Current liabilities The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.
Current Prepayments And Other Current Assets ifrs/2024 0 0 monetary I D Current prepayments and other current assets The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]
Current Trade Receivables ifrs/2024 0 0 monetary I D Current trade receivables The amount of current trade receivables. [Refer: Trade receivables]
Effect Of Exchange Rate Changes On Cash And Cash Equivalents ifrs/2024 0 0 monetary D D Effect of exchange rate changes on cash and cash equivalents The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]
Income Tax Expense Continuing Operations ifrs/2024 0 0 monetary D D Tax expense (income) The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]
Miscellaneous Other Operating Expense ifrs/2024 0 0 monetary D D Miscellaneous other operating expense The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]
Other Current Financial Assets ifrs/2024 0 0 monetary I D Other current financial assets The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]
Purchase Of Intangible Assets Classified As Investing Activities ifrs/2024 0 0 monetary D C Purchase of intangible assets, classified as investing activities The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]
Share Based Payment Expense Incl. Deferred Taxes 0001410578-25-000692 1 0 monetary D C Share-based payment expense (incl. deferred taxes) Amount of Share-based payment expense (incl. deferred taxes)
Adjustments For Decrease Increase In Trade Receivables Contract Assets Assets Held For Sale And Other Assets 0001410578-25-001369 1 0 monetary D D Adjustments for Decrease (Increase) in Trade Receivables, Contract Assets, Assets Held for Sale and Other Assets Adjustments for decrease (increase) in trade receivables, contract assets, assets held for sale and other assets to reconcile profit (loss) to net cash flow from (used in) operating activities.
Adjustments For Other Operating Expense Income 0001410578-25-001369 1 0 monetary D D Adjustments for Other Operating Expense (Income) Adjustments for other operating expenses (income) to reconcile profit (loss) to net cash flow from (used in) operating activities.
Adjustments For Gain Loss On Disposals Property Plant And Equipment ifrs/2024 0 0 monetary D C Adjustments for gain (loss) on disposals, property, plant and equipment Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]
Adjustments For Finance Costs ifrs/2024 0 0 monetary D D Adjustments for finance costs Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]
Adjustments For Losses Gains On Disposal Of Noncurrent Assets ifrs/2024 0 0 monetary D D Adjustments for losses (gains) on disposal of non-current assets Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]
Noncurrent Liabilities ifrs/2024 0 0 monetary I C Non-current liabilities The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]
Assets ifrs/2024 0 0 monetary I D Assets The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.
Current Contract Assets ifrs/2024 0 0 monetary I D Current contract assets The amount of current contract assets. [Refer: Contract assets]
Diluted Earnings Loss Per Share ifrs/2024 0 0 perShare D Diluted earnings (loss) per share The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]
Other Noncurrent Liabilities ifrs/2024 0 0 monetary I C Other non-current liabilities The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]
Payments Of Lease Liabilities Classified As Financing Activities ifrs/2024 0 0 monetary D C Payments of lease liabilities, classified as financing activities The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]
Property Plant And Equipment ifrs/2024 0 0 monetary I D Property, plant and equipment The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]
Research And Development Expense ifrs/2024 0 0 monetary D D Research and development expense The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.
Adjustments Transfer To Asset Held For Sale 0001410578-25-000692 1 0 monetary D D Adjustments Transfer To Asset Held For Sale Amount of transfer to assets held for sale.
Ifrs Stock Issued During Period Value New Issues 0001410578-25-000692 1 0 monetary D C Ifrs Stock Issued During Period Value New Issues The amount of accrued other liability for up-front payment.
Impairments Of Inventory And Prepayments 0001410578-25-000692 1 0 monetary D D Impairments of inventory and prepayments Impairments of inventory and prepayments
Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss ifrs/2024 0 0 monetary D D Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]
Capital Reserve ifrs/2024 0 0 monetary I C Capital reserve A component of equity representing the capital reserves.
Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities ifrs/2024 0 0 monetary D C Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Total for all subsidiaries [member]]
Current Tax Liabilities ifrs/2024 0 0 monetary I C Current tax liabilities The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.
Finance Income ifrs/2024 0 0 monetary D C Finance income The amount of income associated with interest and other financing activities of the entity.
Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners ifrs/2024 0 0 monetary I D Non-current assets or disposal groups classified as held for sale or as held for distribution to owners The amount of non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Non-current assets or disposal groups classified as held for distribution to owners; Non-current assets or disposal groups classified as held for sale]
Sales And Marketing Expense ifrs/2024 0 0 monetary D D Sales and marketing expense The amount of expense relating to the marketing and selling of goods or services.
Settlement Of Share Based Payment Awards Amount 0001410578-25-001369 1 0 monetary D C Settlement Of Share Based Payment Awards , Amount The amount of share based payment awards settled in cash.
Proceed From Issuing Other Equity Instrument Or Exercise Of Options 0001410578-25-001369 1 0 monetary D D Proceed From Issuing Other Equity Instrument Or Exercise of Options Amount of proceed from issuing other equity instrument or exercise of options.
Share Based Payment Expense Incl. Deferred Taxes 0001410578-25-001369 1 0 monetary D C Share-based payment expense (incl. deferred taxes) Amount of Share-based payment expense (incl. deferred taxes)
Interest Paid Classified As Operating Activities ifrs/2024 0 0 monetary D C Interest paid, classified as operating activities The cash outflow for interest paid, classified as operating activities.
Cash Flows From Used In Financing Activities ifrs/2024 0 0 monetary D D Cash flows from (used in) financing activities The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.
Other Comprehensive Income Net Of Tax Exchange Differences On Translation ifrs/2024 0 0 monetary D C Other comprehensive income, net of tax, exchange differences on translation of foreign operations The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]
Liabilities ifrs/2024 0 0 monetary I C Liabilities The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.
Noncurrent Assets ifrs/2024 0 0 monetary I D Non-current assets The amount of assets that do not meet the definition of current assets. [Refer: Current assets]
Profit Loss ifrs/2024 0 0 monetary D C Profit (loss) The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]
Cash Flows From Used In Investing Activities ifrs/2024 0 0 monetary D D Cash flows from (used in) investing activities The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.
Cost Of Sales ifrs/2024 0 0 monetary D D Cost of sales The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.
Equity ifrs/2024 0 0 monetary I C Equity The amount of residual interest in the assets of the entity after deducting all its liabilities.
Intangible Assets And Goodwill ifrs/2024 0 0 monetary I D Intangible assets and goodwill The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]
Noncurrent Contract Liabilities ifrs/2024 0 0 monetary I C Non-current contract liabilities The amount of non-current contract liabilities. [Refer: Contract liabilities]
Revenue From Contracts With Customers ifrs/2024 0 0 monetary D C Revenue from contracts with customers The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity?s ordinary activities in exchange for consideration.
Adjustments For Increase Decrease In Trade And Other Payables ifrs/2024 0 0 monetary D D Adjustments for increase (decrease) in trade and other payables Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]
Current Assets ifrs/2024 0 0 monetary I D Current assets The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]
Deferred Tax Liabilities ifrs/2024 0 0 monetary I C Deferred tax liabilities The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]
Finance Costs ifrs/2024 0 0 monetary D D Finance costs The amount of costs associated with financing activities of the entity.
Issue Of Equity ifrs/2024 0 0 monetary D C Issue of equity The increase in equity through the issue of equity instruments.
Miscellaneous Other Operating Income ifrs/2024 0 0 monetary D C Miscellaneous other operating income The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]
Noncurrent Lease Liabilities ifrs/2024 0 0 monetary I C Non-current lease liabilities The amount of non-current lease liabilities. [Refer: Lease liabilities]
Adjustments For Finance Income ifrs/2024 0 0 monetary D C Adjustments for finance income Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]
Adjustments For Decrease Increase In Trade Receivables Contract Assets Assets Held For Sale And Other Assets 0001410578-25-000692 1 0 monetary D D Adjustments for Decrease (Increase) in Trade Receivables, Contract Assets, Assets Held for Sale and Other Assets Adjustments for decrease (increase) in trade receivables, contract assets, assets held for sale and other assets to reconcile profit (loss) to net cash flow from (used in) operating activities.
Basic Earnings Loss Per Share ifrs/2024 0 0 perShare D Basic earnings (loss) per share The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).
Current Provisions ifrs/2024 0 0 monetary I C Current provisions The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]
Current Tax Assets Current ifrs/2024 0 0 monetary I D Current tax assets, current The current amount of current tax assets. [Refer: Current tax assets]
Increase Decrease In Contingent Consideration Asset Liability ifrs/2024 0 0 monetary D D Increase (decrease) in contingent consideration asset (liability) The increase (decrease) in a contingent consideration asset (liability) relating to a business combination.
Interest Received Classified As Operating Activities ifrs/2024 0 0 monetary D D Interest received, classified as operating activities The cash inflow from interest received, classified as operating activities.
Other Current Liabilities ifrs/2024 0 0 monetary I C Other current liabilities The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]
Other Noncurrent Assets ifrs/2024 0 0 monetary I D Other non-current assets The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]
Rightofuse Assets ifrs/2024 0 0 monetary I D Right-of-use assets The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.
Adjustments For Sharebased Payments ifrs/2024 0 0 monetary D D Adjustments for share-based payments Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]
Cash Flows From Used In Operating Activities ifrs/2024 0 0 monetary D Cash flows from (used in) operating activities The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]
Current Contract Liabilities ifrs/2024 0 0 monetary I C Current contract liabilities The amount of current contract liabilities. [Refer: Contract liabilities]
Issued Capital ifrs/2024 0 0 monetary I C Issued capital The nominal value of capital issued.
Net Deferred Tax Assets ifrs/2024 0 0 monetary I D Net deferred tax assets The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]
Other Comprehensive Income ifrs/2024 0 0 monetary D C Other comprehensive income The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]
Proceed From Issuing Other Equity Instrument Or Exercise Of Options 0001410578-25-000692 1 0 monetary D D Proceed From Issuing Other Equity Instrument Or Exercise of Options Amount of proceed from issuing other equity instrument or exercise of options.
Settlement Of Share Based Payment Awards Amount 0001410578-25-000692 1 0 monetary D C Settlement Of Share Based Payment Awards , Amount The amount of share based payment awards settled in cash.

Description
Field Name Field Description
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
custom 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns.
abstract 1 if the tag is not used to represent a numeric fact.
datatype If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag.
iord If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration.
crdr If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL.
tlabel If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here.
doc The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL.

Presentation of Statements

adsh report line stmt inpth rfile tag version plabel negating
0001410578-25-000692 2 1 IS 0 H Revenue From Contracts With Customers ifrs/2024 Revenue 0
0001410578-25-000692 2 2 IS 0 H Cost Of Sales ifrs/2024 Cost of sales 1
0001410578-25-000692 2 3 IS 0 H Sales And Marketing Expense ifrs/2024 Selling and distribution expenses 1
0001410578-25-000692 2 4 IS 0 H Research And Development Expense ifrs/2024 Research and development expenses 1
0001410578-25-000692 2 5 IS 0 H General And Administrative Expense ifrs/2024 General and administrative expenses 1
0001410578-25-000692 2 6 IS 0 H Miscellaneous Other Operating Income ifrs/2024 Other operating income 0
0001410578-25-000692 2 7 IS 0 H Miscellaneous Other Operating Expense ifrs/2024 Other operating expenses 1
0001410578-25-000692 2 8 IS 0 H Profit Loss From Operating Activities ifrs/2024 Operating profit / (loss) 0
0001410578-25-000692 2 9 IS 0 H Finance Income ifrs/2024 Finance income 0
0001410578-25-000692 2 10 IS 0 H Finance Costs ifrs/2024 Finance expenses 1
0001410578-25-000692 2 11 IS 0 H Profit Loss Before Tax ifrs/2024 Profit / (Loss) before income tax 0
0001410578-25-000692 2 12 IS 0 H Income Tax Expense Continuing Operations ifrs/2024 Income tax benefit/ (expense) 1
0001410578-25-000692 2 13 IS 0 H Profit Loss ifrs/2024 Net profit / (loss) for the period 0
0001410578-25-000692 2 15 IS 0 H Other Comprehensive Income Net Of Tax Exchange Differences On Translation ifrs/2024 Foreign currency adjustments 0
0001410578-25-000692 2 16 IS 0 H Comprehensive Income ifrs/2024 Total comprehensive income / (loss) for the period 0
0001410578-25-000692 2 17 IS 0 H Basic Earnings Loss Per Share ifrs/2024 Net profit / (loss) loss per share - basic (in dollars per share) 0
0001410578-25-000692 2 18 IS 0 H Diluted Earnings Loss Per Share ifrs/2024 Net profit / (loss) loss per share - diluted (in dollars per share) 0
0001410578-25-000692 3 3 BS 0 H Intangible Assets And Goodwill ifrs/2024 Intangible assets and goodwill 0
0001410578-25-000692 3 4 BS 0 H Property Plant And Equipment ifrs/2024 Property, plant and equipment 0
0001410578-25-000692 3 5 BS 0 H Rightofuse Assets ifrs/2024 Right-of-use assets 0
0001410578-25-000692 3 6 BS 0 H Other Noncurrent Assets ifrs/2024 Other assets 0
0001410578-25-000692 3 7 BS 0 H Net Deferred Tax Assets ifrs/2024 Deferred tax assets 0
0001410578-25-000692 3 8 BS 0 H Noncurrent Assets ifrs/2024 Total non-current assets 0
0001410578-25-000692 3 10 BS 0 H Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners ifrs/2024 Assets held for sale 0
0001410578-25-000692 3 11 BS 0 H Inventories ifrs/2024 Inventories 0
0001410578-25-000692 3 12 BS 0 H Current Trade Receivables ifrs/2024 Trade receivables 0
0001410578-25-000692 3 13 BS 0 H Current Contract Assets ifrs/2024 Contract assets 0
0001410578-25-000692 3 14 BS 0 H Other Current Financial Assets ifrs/2024 Other financial assets 0
0001410578-25-000692 3 15 BS 0 H Current Prepayments And Other Current Assets ifrs/2024 Prepaid expenses and other assets 0
0001410578-25-000692 3 16 BS 0 H Current Tax Assets Current ifrs/2024 Current tax assets 0
0001410578-25-000692 3 17 BS 0 H Cash And Cash Equivalents ifrs/2024 Cash and cash equivalents 0
0001410578-25-000692 3 18 BS 0 H Current Assets ifrs/2024 Total current assets 0
0001410578-25-000692 3 19 BS 0 H Assets ifrs/2024 Total assets 0
0001410578-25-000692 3 22 BS 0 H Issued Capital ifrs/2024 Issued capital 0
0001410578-25-000692 3 23 BS 0 H Capital Reserve ifrs/2024 Capital reserve 0
0001410578-25-000692 3 24 BS 0 H Retained Earnings ifrs/2024 Accumulated deficit 0
0001410578-25-000692 3 25 BS 0 H Accumulated Other Comprehensive Income ifrs/2024 Other comprehensive income 0
0001410578-25-000692 3 26 BS 0 H Equity ifrs/2024 Total equity 0
0001410578-25-000692 3 28 BS 0 H Noncurrent Lease Liabilities ifrs/2024 Lease liabilities 0
0001410578-25-000692 3 29 BS 0 H Noncurrent Contract Liabilities ifrs/2024 Contract liabilities 0
0001410578-25-000692 3 30 BS 0 H Deferred Tax Liabilities ifrs/2024 Deferred tax liabilities 0
0001410578-25-000692 3 31 BS 0 H Noncurrent Liabilities ifrs/2024 Total non-current liabilities 0
0001410578-25-000692 3 33 BS 0 H Current Lease Liabilities ifrs/2024 Lease liabilities 0
0001410578-25-000692 3 34 BS 0 H Trade And Other Current Payables ifrs/2024 Trade and other payables 0
0001410578-25-000692 3 35 BS 0 H Current Provisions ifrs/2024 Provisions 0
0001410578-25-000692 3 36 BS 0 H Other Current Liabilities ifrs/2024 Other liabilities 0
0001410578-25-000692 3 37 BS 0 H Current Tax Liabilities ifrs/2024 Income taxes payable 0
0001410578-25-000692 3 38 BS 0 H Current Contract Liabilities ifrs/2024 Contract liabilities 0
0001410578-25-000692 3 39 BS 0 H Current Liabilities ifrs/2024 Total current liabilities 0
0001410578-25-000692 3 40 BS 0 H Liabilities ifrs/2024 Total liabilities 0
0001410578-25-000692 3 41 BS 0 H Equity And Liabilities ifrs/2024 Total equity and liabilities 0
0001410578-25-000692 4 10 EQ 0 H Equity ifrs/2024 Balance at the beginning 0
0001410578-25-000692 4 11 EQ 0 H Profit Loss ifrs/2024 Net profit / (loss) 0
0001410578-25-000692 4 12 EQ 0 H Other Comprehensive Income ifrs/2024 Other comprehensive income (loss) 0
0001410578-25-000692 4 13 EQ 0 H Comprehensive Income ifrs/2024 Total comprehensive income (loss) 0
0001410578-25-000692 4 14 EQ 0 H Share Based Payment Expense Incl. Deferred Taxes 0001410578-25-000692 Share-based payment expense 0
0001410578-25-000692 4 15 EQ 0 H Issue Of Equity ifrs/2024 Issuance of share capital (net of transaction costs) 0
0001410578-25-000692 4 16 EQ 0 H Tax Benefit Arising From Previously Unrecognised Tax Loss Tax Credit Or Temporary Difference Of Prior Period Used To Reduce Current Tax Expense ifrs/2024 Realized tax benefits on transaction costs of prior years 0
0001410578-25-000692 4 17 EQ 0 H Increase Decrease In Contingent Consideration Asset Liability ifrs/2024 Share issuances and contingent consideration from business combination 1
0001410578-25-000692 4 18 EQ 0 H Exercise Of Options Settlement Of Share Based Payment Awards Amount 0001410578-25-000692 Exercise of options / Settlement of share-based payment awards 0
0001410578-25-000692 4 19 EQ 0 H Settlement Of Share Based Payment Awards Amount 0001410578-25-000692 Settlement of share-based payment awards 0
0001410578-25-000692 4 20 EQ 0 H Equity ifrs/2024 Balance at the end 0
0001410578-25-000692 5 2 CF 0 H Profit Loss Before Tax ifrs/2024 Profit / (Loss) before income tax 0
0001410578-25-000692 5 4 CF 0 H Adjustments For Finance Income ifrs/2024 Finance income 1
0001410578-25-000692 5 5 CF 0 H Adjustments For Finance Costs ifrs/2024 Finance expense 0
0001410578-25-000692 5 6 CF 0 H Depreciation And Amortisation Expense ifrs/2024 Depreciation and amortization 0
0001410578-25-000692 5 7 CF 0 H Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss ifrs/2024 Impairment of intangible assets and property, plant and equipment 0
0001410578-25-000692 5 8 CF 0 H Adjustments For Losses Gains On Disposal Of Noncurrent Assets ifrs/2024 Loss on disposal of non-current assets 0
0001410578-25-000692 5 9 CF 0 H Adjustments Transfer To Asset Held For Sale 0001410578-25-000692 Impairment of assets held for sale 0
0001410578-25-000692 5 10 CF 0 H Impairments Of Inventory And Prepayments 0001410578-25-000692 Impairment of inventory 0
0001410578-25-000692 5 11 CF 0 H Adjustments For Sharebased Payments ifrs/2024 Share-based payment expense 0
0001410578-25-000692 5 13 CF 0 H Adjustments For Decrease Increase In Inventories ifrs/2024 Decrease / (increase) in inventory 0
0001410578-25-000692 5 14 CF 0 H Adjustments For Decrease Increase In Trade Receivables Contract Assets Assets Held For Sale And Other Assets 0001410578-25-000692 Decrease in trade receivables, contract assets, asset held for sale and other assets 0
0001410578-25-000692 5 15 CF 0 H Adjustments For Increase Decrease In Trade And Other Payables ifrs/2024 Decrease in trade and other payables and contract liabilities 0
0001410578-25-000692 5 16 CF 0 H Adjustments For Increase Decrease In Provisions 0001410578-25-000692 Decrease in provisions 0
0001410578-25-000692 5 17 CF 0 H Income Taxes Paid Classified As Operating Activities ifrs/2024 Income taxes paid 1
0001410578-25-000692 5 18 CF 0 H Interest Received Classified As Operating Activities ifrs/2024 Interest received 0
0001410578-25-000692 5 19 CF 0 H Interest Paid Classified As Operating Activities ifrs/2024 Interest paid 1
0001410578-25-000692 5 20 CF 0 H Cash Flows From Used In Operating Activities ifrs/2024 Net cash flow provided by / (used in) operating activities 0
0001410578-25-000692 5 22 CF 0 H Purchase Of Property Plant And Equipment Classified As Investing Activities ifrs/2024 Purchase of property, plant and equipment 1
0001410578-25-000692 5 23 CF 0 H Purchase Of Intangible Assets Classified As Investing Activities ifrs/2024 Purchase of intangible assets 1
0001410578-25-000692 5 24 CF 0 H Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities ifrs/2024 Acquisition of subsidiary, net of cash acquired 1
0001410578-25-000692 5 25 CF 0 H Cash Flows From Used In Investing Activities ifrs/2024 Net cash flow provided by / (used in) investing activities 0
0001410578-25-000692 5 27 CF 0 H Payments Of Lease Liabilities Classified As Financing Activities ifrs/2024 Payments on lease obligations 1
0001410578-25-000692 5 28 CF 0 H Proceeds From Issuing Shares ifrs/2024 Proceeds from the issuance of shares (net of transaction costs) 0
0001410578-25-000692 5 29 CF 0 H Proceed From Issuing Other Equity Instrument Or Exercise Of Options 0001410578-25-000692 Payment on / proceeds from treasury shares/exercise of options 0
0001410578-25-000692 5 30 CF 0 H Ifrs Stock Issued During Period Value New Issues 0001410578-25-000692 Proceeds from at-the-market offering program (net of transaction costs) 1
0001410578-25-000692 5 32 CF 0 H Cash Flows From Used In Financing Activities ifrs/2024 Net cash flow provided by / (used in) financing activities 0
0001410578-25-000692 5 33 CF 0 H Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes ifrs/2024 Net increase / (decrease) in cash and cash equivalents 0
0001410578-25-000692 5 34 CF 0 H Effect Of Exchange Rate Changes On Cash And Cash Equivalents ifrs/2024 Effect of exchange rate changes on cash and cash equivalents 0
0001410578-25-000692 5 35 CF 0 H Cash And Cash Equivalents ifrs/2024 Cash and cash equivalents, beginning of period 0
0001410578-25-000692 5 36 CF 0 H Cash And Cash Equivalents ifrs/2024 Cash and cash equivalents, end of period 0
0001410578-25-001369 3 22 BS 0 H Issued Capital ifrs/2024 Issued capital 0
0001410578-25-001369 2 1 IS 0 H Revenue From Contracts With Customers ifrs/2024 Revenue 0
0001410578-25-001369 2 2 IS 0 H Cost Of Sales ifrs/2024 Cost of sales 1
0001410578-25-001369 2 3 IS 0 H Sales And Marketing Expense ifrs/2024 Selling and distribution expenses 1
0001410578-25-001369 2 4 IS 0 H Research And Development Expense ifrs/2024 Research and development expenses 1
0001410578-25-001369 2 5 IS 0 H General And Administrative Expense ifrs/2024 General and administrative expenses 1
0001410578-25-001369 2 6 IS 0 H Miscellaneous Other Operating Income ifrs/2024 Other operating income 0
0001410578-25-001369 2 7 IS 0 H Miscellaneous Other Operating Expense ifrs/2024 Other operating expenses 1
0001410578-25-001369 2 8 IS 0 H Profit Loss From Operating Activities ifrs/2024 Operating loss 0
0001410578-25-001369 2 9 IS 0 H Finance Income ifrs/2024 Finance income 0
0001410578-25-001369 2 10 IS 0 H Finance Costs ifrs/2024 Finance expenses 1
0001410578-25-001369 2 11 IS 0 H Profit Loss Before Tax ifrs/2024 Loss before income tax 0
0001410578-25-001369 2 12 IS 0 H Income Tax Expense Continuing Operations ifrs/2024 Income tax benefit/ (expense) 1
0001410578-25-001369 2 13 IS 0 H Profit Loss ifrs/2024 Net loss for the period 0
0001410578-25-001369 2 16 IS 0 H Other Comprehensive Income Net Of Tax Exchange Differences On Translation ifrs/2024 Foreign currency adjustments 0
0001410578-25-001369 2 17 IS 0 H Comprehensive Income ifrs/2024 Total comprehensive loss for the period 0
0001410578-25-001369 2 18 IS 0 H Basic Earnings Loss Per Share ifrs/2024 Net loss per share - basic (in dollars per share) 0
0001410578-25-001369 2 19 IS 0 H Diluted Earnings Loss Per Share ifrs/2024 Net loss per share - diluted (in dollars per share) 0
0001410578-25-001369 3 3 BS 0 H Intangible Assets And Goodwill ifrs/2024 Intangible assets and goodwill 0
0001410578-25-001369 3 4 BS 0 H Property Plant And Equipment ifrs/2024 Property, plant and equipment 0
0001410578-25-001369 3 5 BS 0 H Rightofuse Assets ifrs/2024 Right-of-use assets 0
0001410578-25-001369 3 6 BS 0 H Other Noncurrent Assets ifrs/2024 Other assets 0
0001410578-25-001369 3 7 BS 0 H Net Deferred Tax Assets ifrs/2024 Deferred tax assets 0
0001410578-25-001369 3 8 BS 0 H Noncurrent Assets ifrs/2024 Total non-current assets 0
0001410578-25-001369 3 10 BS 0 H Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners ifrs/2024 Assets held for sale 0
0001410578-25-001369 3 11 BS 0 H Inventories ifrs/2024 Inventories 0
0001410578-25-001369 3 12 BS 0 H Current Trade Receivables ifrs/2024 Trade receivables 0
0001410578-25-001369 3 13 BS 0 H Current Contract Assets ifrs/2024 Contract assets 0
0001410578-25-001369 3 14 BS 0 H Other Current Financial Assets ifrs/2024 Other financial assets 0
0001410578-25-001369 3 15 BS 0 H Current Prepayments And Other Current Assets ifrs/2024 Prepaid expenses and other assets 0
0001410578-25-001369 3 16 BS 0 H Current Tax Assets Current ifrs/2024 Current tax assets 0
0001410578-25-001369 3 17 BS 0 H Cash And Cash Equivalents ifrs/2024 Cash and cash equivalents 0
0001410578-25-001369 3 18 BS 0 H Current Assets ifrs/2024 Total current assets 0
0001410578-25-001369 3 19 BS 0 H Assets ifrs/2024 Total assets 0
0001410578-25-001369 3 23 BS 0 H Capital Reserve ifrs/2024 Capital reserve 0
0001410578-25-001369 3 24 BS 0 H Retained Earnings ifrs/2024 Accumulated deficit 0
0001410578-25-001369 3 25 BS 0 H Accumulated Other Comprehensive Income ifrs/2024 Other comprehensive income 0
0001410578-25-001369 3 26 BS 0 H Equity ifrs/2024 Total equity 0
0001410578-25-001369 3 28 BS 0 H Noncurrent Lease Liabilities ifrs/2024 Lease liabilities 0
0001410578-25-001369 3 29 BS 0 H Deferred Tax Liabilities ifrs/2024 Deferred tax liabilities 0
0001410578-25-001369 3 30 BS 0 H Other Noncurrent Liabilities ifrs/2024 Other liabilities 0
0001410578-25-001369 3 31 BS 0 H Noncurrent Liabilities ifrs/2024 Total non-current liabilities 0
0001410578-25-001369 3 33 BS 0 H Current Lease Liabilities ifrs/2024 Lease liabilities 0
0001410578-25-001369 3 34 BS 0 H Trade And Other Current Payables ifrs/2024 Trade and other payables 0
0001410578-25-001369 3 35 BS 0 H Current Provisions ifrs/2024 Provisions 0
0001410578-25-001369 3 36 BS 0 H Other Current Liabilities ifrs/2024 Other liabilities 0
0001410578-25-001369 3 37 BS 0 H Current Tax Liabilities ifrs/2024 Income taxes payable 0
0001410578-25-001369 3 38 BS 0 H Current Liabilities ifrs/2024 Total current liabilities 0
0001410578-25-001369 3 39 BS 0 H Liabilities ifrs/2024 Total liabilities 0
0001410578-25-001369 3 40 BS 0 H Equity And Liabilities ifrs/2024 Total equity and liabilities 0
0001410578-25-001369 4 9 EQ 0 H Equity ifrs/2024 Balance at the beginning 0
0001410578-25-001369 4 10 EQ 0 H Profit Loss ifrs/2024 Net profit / (loss) 0
0001410578-25-001369 4 11 EQ 0 H Other Comprehensive Income ifrs/2024 Other comprehensive income (loss) 0
0001410578-25-001369 4 12 EQ 0 H Comprehensive Income ifrs/2024 Total comprehensive income (loss) 0
0001410578-25-001369 4 13 EQ 0 H Share Based Payment Expense Incl. Deferred Taxes 0001410578-25-001369 Share-based payment expense 0
0001410578-25-001369 4 14 EQ 0 H Tax Benefit Arising From Previously Unrecognised Tax Loss Tax Credit Or Temporary Difference Of Prior Period Used To Reduce Current Tax Expense ifrs/2024 Realized tax benefits on transaction costs of prior years 0
0001410578-25-001369 4 15 EQ 0 H Settlement Of Share Based Payment Awards Amount 0001410578-25-001369 Settlement of share-based payment awards 0
0001410578-25-001369 4 16 EQ 0 H Equity ifrs/2024 Balance at the end 0
0001410578-25-001369 5 2 CF 0 H Profit Loss Before Tax ifrs/2024 Loss before income tax 0
0001410578-25-001369 5 4 CF 0 H Adjustments For Finance Income ifrs/2024 Finance income 1
0001410578-25-001369 5 5 CF 0 H Adjustments For Finance Costs ifrs/2024 Finance expense 0
0001410578-25-001369 5 6 CF 0 H Depreciation And Amortisation Expense ifrs/2024 Depreciation and amortization 0
0001410578-25-001369 5 7 CF 0 H Adjustments For Gain Loss On Disposals Property Plant And Equipment ifrs/2024 Loss on disposal of fixed assets 1
0001410578-25-001369 5 8 CF 0 H Adjustments For Sharebased Payments ifrs/2024 Share-based payment expense 0
0001410578-25-001369 5 9 CF 0 H Adjustments For Other Operating Expense Income 0001410578-25-001369 Other operating income 0
0001410578-25-001369 5 11 CF 0 H Adjustments For Decrease Increase In Trade Receivables Contract Assets Assets Held For Sale And Other Assets 0001410578-25-001369 Decrease in trade receivables, contract assets, assets held for sale and other assets 0
0001410578-25-001369 5 12 CF 0 H Adjustments For Decrease Increase In Inventories ifrs/2024 Increase in inventory 0
0001410578-25-001369 5 13 CF 0 H Adjustments For Increase Decrease In Trade And Other Payables ifrs/2024 Decrease in trade and other payables, other liabilities and contract liabilities 0
0001410578-25-001369 5 14 CF 0 H Adjustments For Provisions ifrs/2024 (Decrease) / increase in provisions 0
0001410578-25-001369 5 15 CF 0 H Income Taxes Paid Classified As Operating Activities ifrs/2024 Income taxes paid 1
0001410578-25-001369 5 16 CF 0 H Interest Received Classified As Operating Activities ifrs/2024 Interest received 0
0001410578-25-001369 5 17 CF 0 H Interest Paid Classified As Operating Activities ifrs/2024 Interest paid 1
0001410578-25-001369 5 18 CF 0 H Cash Flows From Used In Operating Activities ifrs/2024 Net cash flow used in operating activities 0
0001410578-25-001369 5 20 CF 0 H Purchase Of Property Plant And Equipment Classified As Investing Activities ifrs/2024 Purchase of property, plant and equipment 1
0001410578-25-001369 5 21 CF 0 H Purchase Of Intangible Assets Classified As Investing Activities ifrs/2024 Purchase of intangible assets 1
0001410578-25-001369 5 22 CF 0 H Cash Flows From Used In Investing Activities ifrs/2024 Net cash flow used in investing activities 0
0001410578-25-001369 5 24 CF 0 H Payments Of Lease Liabilities Classified As Financing Activities ifrs/2024 Payments on lease obligations 1
0001410578-25-001369 5 25 CF 0 H Proceed From Issuing Other Equity Instrument Or Exercise Of Options 0001410578-25-001369 Payment on / proceeds from treasury shares/exercise of options 0
0001410578-25-001369 5 26 CF 0 H Cash Flows From Used In Financing Activities ifrs/2024 Net cash flow used in financing activities 0
0001410578-25-001369 5 27 CF 0 H Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes ifrs/2024 Net decrease in cash and cash equivalents 0
0001410578-25-001369 5 28 CF 0 H Effect Of Exchange Rate Changes On Cash And Cash Equivalents ifrs/2024 Effect of exchange rate changes on cash and cash equivalents 0
0001410578-25-001369 5 29 CF 0 H Cash And Cash Equivalents ifrs/2024 Cash and cash equivalents, beginning of period 0
0001410578-25-001369 5 30 CF 0 H Cash And Cash Equivalents ifrs/2024 Cash and cash equivalents, end of period 0

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
report Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site.
line Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived.
stmt The financial statement location to which the value of the “report” field pertains.
inpth Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700.
rfile The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file.
tag The tag chosen by the filer for this line item.
version The taxonomy identifier if the tag is a standard tag, otherwise adsh.
plabel The text presented on the line item, also known as a “preferred” label.
negating Flag to indicate whether the plabel is negating.